Gentamicin-Attenuated Leishmania infantum Vaccine: Protection of Dogs against Canine Visceral Leishmaniosis in Endemic Area of Southeast of Iran
Open Access
- 17 April 2014
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 8 (4) , e2757
Abstract
An attenuated line of Leishmania infantum (L. infantum H-line) has been established by culturing promastigotes in vitro under gentamicin pressure. A vaccine trial was conducted using 103 naive dogs from a leishmaniosis non-endemic area (55 vaccinated and 48 unvaccinated) brought into an endemic area of southeast Iran. No local and/or general indications of disease were observed in the vaccinated dogs immediately after vaccination. The efficacy of the vaccine was evaluated after 24 months (4 sandfly transmission seasons) by serological, parasitological analyses and clinical examination. In western blot analysis of antibodies to L. infantum antigens, sera from 10 out of 31 (32.2%) unvaccinated dogs, but none of the sera from vaccinated dogs which were seropositive at >100, recognized the 21 kDa antigen of L. infantum wild-type (WT). Nine out of 31 (29%) unvaccinated dogs, but none of vaccinated dogs, were positive for the presence of Leishmania DNA. One out of 46 (2.2%) vaccinated dogs and 9 out of 31 (29%) unvaccinated dogs developed clinical signs of disease. These results suggest that gentamicin-attenuated L. infantum induced a significant and strong protective effect against canine visceral leishmaniosis in the endemic area. A 24 month vaccine trial was conducted using 103 leishmania free dogs in an area of southeast Iran endemic for visceral leishmaniosis. The dogs were vaccinated with gentamicin-attenuated line of Leishmania infantum. No local and/or general indications of disease were observed in the vaccinated dogs immediately after vaccination with an attenuated line of Leishmania infantum. Nine out of 31 (29%) unvaccinated dogs, but none of those vaccinated, were positive for presence of Leishmania DNA by PCR. In western blots, sera from 10 out of 31 (32.2%) unvaccinated dogs, but none of the sera from vaccinated dogs, recognized the 21 kDa antigen of Leishmania infantum wild-type. One out of 46 (2.2%) vaccinated dogs and 9 out of 31 (29%) unvaccinated dogs developed clinical signs of disease. The attenuated Leishmania infantum induced a significant and strong protective effect against Leishmania infantum infection in the field.Keywords
This publication has 37 references indexed in Scilit:
- KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral LeishmaniasisClinical and Vaccine Immunology, 2011
- LeishVet guidelines for the practical management of canine leishmaniosisParasites & Vectors, 2011
- Gentamicin‐attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasisParasite Immunology, 2010
- Optimized subunit vaccine protects against experimental leishmaniasisVaccine, 2009
- Gentamicin-attenuated Leishmania infantum: A clinicopathological study in dogsVeterinary Immunology and Immunopathology, 2009
- Toward Diagnosing Leishmania infantum Infection in Asymptomatic Dogs in an Area Where Leishmaniasis Is EndemicClinical and Vaccine Immunology, 2009
- Canine leishmaniosis in South AmericaParasites & Vectors, 2009
- Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part oneTrends in Parasitology, 2008
- Leishmania mexicanaandLeishmania major:Attenuation of Wild‐Type Parasites and Vaccination with the Attenuated LinesThe Journal of Infectious Diseases, 2003
- A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S o Gon alo do Amaranto, RN)Vaccine, 2000